LINC 2023: Late-breaking Science Video Collection

Published: 20 June 2023

Views:
781
Likes:
7

Views:
781
Likes:
7
Share:

Now Playing
Part 1 | Session 1 of 9
AVPAS: Lutonix AV Post-Approval Study
Scott O Trerotola

Up Next
5m 18s

Part 1 | Session 2 The ELEGANCE Registry: Ranger DCB In Under-Represented Groups
Marianne Brodmann
4m 51s

Part 1 | Session 3 RANGER II SFA: 3 Year Patency and 4 Year Clinical Safety
Marianne Brodmann
4m 48s

Part 1 | Session 4 IN.PACT AV ACCESS: Outcomes to Date
Matteo Tozzi
8m 14s

Part 1 | Session 5 TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes
Koen Deloose
7m 13s

Part 1 | Session 6 POPCORN Registry: DCB Treatment for Peripheral Artery Disease
Yoshimitsu Soga
3m 49s

Part 1 | Session 7 MOTIV Bioresorbable Scaffold in BTK Lesions
Michel Bosiers
6m 6s

Part 1 | Session 8 Improving Clinical Outcomes in Infrapopliteal Lesions With Cre8™ BTK
Marc Sirvent
8m 56s

Part 1 | Session 9 LIFE-BTK: Esprit BTK System in Narrowed Infrapopliteal Lesions
Sahil Parikh

Average (ratings)

No ratings

Your rating

Overview

Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

Expert Interviews

Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.

9 sessions
AVPAS: Lutonix AV Post-Approval Study	Watch now
The ELEGANCE Registry: Ranger DCB In Under-Represented Groups	Watch now
RANGER II SFA: 3 Year Patency and 4 Year Clinical Safety	Watch now
IN.PACT AV ACCESS: Outcomes to Date	Watch now
TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes	Watch now
POPCORN Registry: DCB Treatment for Peripheral Artery Disease	Watch now
MOTIV Bioresorbable Scaffold in BTK Lesions	Watch now
Improving Clinical Outcomes in Infrapopliteal Lesions With Cre8™ BTK	Watch now
LIFE-BTK: Esprit BTK System in Narrowed Infrapopliteal Lesions	Watch now

About the episode

LINC 23 - Dr Scott Trerotola (Penn Medicine, Philadelphia, PA, US) joins us to discuss the interim findings of the AVPAS Lutonix drug-coated balloon post-approval study.

The Lutonix 035 drug-coated balloon PTA catheter is a low-profile DCB designed to address de novo, restenotic or in-stent restenotic lesions in the superficial femoral and popliteal arteries. Dr Trerotola provides an insight into a prospective, global, multicenter post-approval study into the clinical use and safety of the Lutonix PTA catheter in patients with arteriovenous fistulae in the upper extremity.

Results suggest that this planned interim analysis of 81 patients shows a 6-month target lesion primary patency of 77.6%.

Questions:

What is the reasoning behind this post-approval study?
Tell us about the Lutonix PTA Catheter and its unique features.
What were the study design and patient population?
What were the key findings revealed at LINC 23?
How should these findings impact clinical practice and future research?
What further study is needed?

Recorded remotely from Philadelphia, 2023.
Interviewer: Jordan Rance
Video Specialist: Oliver Miles

Faculty Biographies